

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.



**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

We claim:


1. A compound represented by any of the following structural formulas



5



10



or a pharmaceutically acceptable isomer, salt, solvate or polymorph thereof.

2. A pharmaceutical composition comprising an effective amount of at least one
5 compound of Claim 1 and at least one pharmaceutically acceptable carrier.

3. A method of inhibiting thrombin receptors comprising administering to a
mammal in need of such treatment an effective amount of at least one compound of
Claim 1.


10

4. A method of inhibiting cannabinoid receptors comprising administering to a
mammal in need of such treatment an effective amount of at least one compound of
Claim 1.

15 5. A method of treating thrombosis, platelet aggregation, coagulation, cancer,
inflammatory diseases or respiratory diseases comprising administering to a mammal
in need of such treatment an effective amount of at least one compound of Claim 1.

6. A method of treating atherosclerosis, restenosis, hypertension, angina
20 pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis,
thrombotic stroke, thromboembolytic stroke, peripheral vascular diseases, cerebral
ischemia, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis,
diabetes, osteoporosis, renal ischemia, cerebral stroke, cerebral ischemia, nephritis,
inflammatory disorders of the lungs and gastrointestinal tract, reversible airway
25 obstruction, chronic asthma or bronchitis comprising administering to a mammal in
need of such treatment an effective amount of at least one compound of Claim 1.


7. A compound represented by the following structural formula:



5

or a pharmaceutically acceptable isomer, salt or solvate thereof.


8. A compound represented by the following structural formula



10

or a pharmaceutically acceptable isomer, salt or solvate thereof.


9. A compound represented by the following structural formula



15

or a pharmaceutically acceptable isomer, salt or solvate thereof.


10. A compound represented by the following structural formula



5

or a pharmaceutically acceptable isomer, salt or solvate thereof.


11. A compound represented by the following structural formula



10

or a pharmaceutically acceptable isomer, salt or solvate thereof.


12. A compound represented by the following structural formula



15

or a pharmaceutically acceptable isomer, salt or solvate thereof.


13. A compound represented by the following structural formula



5

or a pharmaceutically acceptable isomer, salt or solvate thereof.


14. A compound represented by the following structural formula



10

or a pharmaceutically acceptable isomer, salt or solvate thereof.


15. A compound represented by the following structural formula



15

or a pharmaceutically acceptable isomer, salt or solvate thereof.

16. A compound represented by the following structural formula



5

or a pharmaceutically acceptable isomer, salt or solvate thereof.